Generis Capital Partners appeared to be the VC, which was created in 2009. The leading representative office of defined VC is situated in the Paris. The fund was located in Europe if to be more exact in France.
The standard case for the fund is to invest in rounds with 2-3 partakers. Despite the Generis Capital Partners, startups are often financed by Piton Capital, Earlybird Venture Capital, DN Capital. The meaningful sponsors for the fund in investment in the same round are Piton Capital, Earlybird Venture Capital, DN Capital. In the next rounds fund is usually obtained by Piton Capital, Earlybird Venture Capital, DN Capital.
The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. Among the various public portfolio startups of the fund, we may underline WeQ, Finexkap, EyeGate Pharmaceuticals For fund there is a match between the country of its foundation and the country of its the most frequent investments - France. Among the most popular fund investment industries, there are Health Care, Pharmaceutical. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.
The increased amount of exits for fund were in 2018. The usual things for fund are deals in the range of 5 - 10 millions dollars. This Generis Capital Partners works on 5 percentage points less the average amount of lead investments comparing to the other organizations. Speaking about the real fund results, this VC is 21 percentage points more often commits exit comparing to other organizations. The fund is constantly included in 2-6 investment rounds annually. The high activity for fund was in 2017. Despite it in 2019 the fund had an activity.
The fund was created by Thibaut de Roux. The overall number of key employees were 6.
Funds with similar focus
|Anova Capital||Beijing, Beijing, China|
|Archer Malmo||Memphis, Tennessee, United States|
|Ascend.vc||Seattle, United States, Washington|
|Capstone Ventures||California, Menlo Park, United States|
|FINTOP Capital||Nashville, Tennessee, United States|
|Integrated Retirement Initiatives||Baxter, Minnesota, United States|
|OPKO Health||Florida, Miami, United States|
|Panyu Shangjian Touzi||China, Guangdong, Guangzhou|
|Raza Venture Fund||California, Cupertino, United States|
|Relativity Healthcare Partners||-|
|Revolution Growth||District of Columbia, United States, Washington|
|Shanghai Baison Software Co||China, Shanghai|
|Shenzhen Haide Hengrun Caijing Zixun Youxian Gongsi||China, Guangdong, Shenzhen|
|TDK Ventures||California, San Jose, United States|
|The Flying Object||District of Columbia, United States, Washington|
|WILLTEC||Japan, Osaka, Osaka Prefecture|
|Yicai Wang||Beijing, China, Haidian|
|$4M||07 Nov 2022||Neuilly-sur-seine, Ile-de-France, France|
|$2M||16 Jun 2022||Paris, Ile-de-France, France|
|$7M||07 Oct 2021||Paris, Ile-de-France, France|
|$5M||26 Jul 2021||Paris, Ile-de-France, France|
|$24M||05 Jul 2021||France, Hauts-de-France, France|
|$5M||20 Apr 2021||Ghent, East Flanders, Belgium|
|$5M||24 Jan 2020||Paris, Ile-de-France, France|
|$1M||23 May 2019||France, Ile-de-France, France|
|$3M||26 Dec 2018||Paris, Ile-de-France, France|
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.